title: MS clinical trials: what can subgroup analyses teach us?
authors.affiliation: Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. rudickr@ccf.org
authors.forename: Richard A
authors.initials: RA
authors.lastname: Rudick
mesh_terms: D004185:Disability Evaluation; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine